121 related articles for article (PubMed ID: 33534409)
21. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
Tranberg M; Jensen JS; Bech BH; Andersen B
BMC Infect Dis; 2020 Dec; 20(1):926. PubMed ID: 33276740
[TBL] [Abstract][Full Text] [Related]
22. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
23. Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.
Ebisch RMF; Ketelaars PJW; van der Sanden WMH; Schmeink CE; Lenselink CH; Siebers AG; Massuger LFAG; Melchers WJG; Bekkers RLM
PLoS One; 2018; 13(10):e0206219. PubMed ID: 30356297
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of High-Risk Human Papillomavirus by RNA Assay in Home Self-Collected Samples Among Underscreened People in North Carolina.
Lee F; Bukowski A; Spees LP; Wheeler SB; Brewer NT; Sanusi B; Hudgens MG; Jackson S; Barclay L; Carter A; Tang JH; Smith JS
Sex Transm Dis; 2022 Mar; 49(3):244-249. PubMed ID: 34535615
[TBL] [Abstract][Full Text] [Related]
25. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
26. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
[TBL] [Abstract][Full Text] [Related]
27. Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study.
Agorastos T; Chatzistamatiou K; Tsertanidou A; Mouchtaropoulou E; Pasentsis K; Kitsou A; Moysiadis T; Moschaki V; Skenderi A; Katsiki E; Aggelidou S; Venizelos I; Ntoula M; Daponte A; Vanakara P; Garas A; Stefos T; Vrekoussis T; Lymberis V; Kontomanolis EN; Makrigiannakis A; Manidakis G; Deligeoroglou E; Panoskaltsis T; Decavalas GO; Michail G; Kalogiannidis I; Koukoulis G; Zempili P; Halatsi D; Truva T; Piha V; Agelena G; Chronopoulou A; Vaitsi V; Chatzaki E; Paschopoulos M; Adonakis G; Kaufmann AM; Hadzidimitriou A; Stamatopoulos K
Cancer Prev Res (Phila); 2019 Oct; 12(10):701-710. PubMed ID: 31427275
[TBL] [Abstract][Full Text] [Related]
28. Symptomatic HPV-related neovaginal lesions in transgender women: case series and review of literature.
van der Sluis WB; Buncamper ME; Bouman MB; Neefjes-Borst EA; Heideman DAM; Steenbergen RDM; Mullender MG
Sex Transm Infect; 2016 Nov; 92(7):499-501. PubMed ID: 27013740
[TBL] [Abstract][Full Text] [Related]
29. CyclinA1 Promoter Methylation in Self-Sampling Test.
Oranratanaphan S; Kengsakul M; Triratanachat S; Kitkumthorn N; Mutirangura A; Termrungruanglert W
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2913-2917. PubMed ID: 33112548
[TBL] [Abstract][Full Text] [Related]
30. Cytology of the neovagina in transgender women and individuals with congenital or acquired absence of a natural vagina.
Grosse A; Grosse C; Lenggenhager D; Bode B; Camenisch U; Bode P
Cytopathology; 2017 Jun; 28(3):184-191. PubMed ID: 28217933
[TBL] [Abstract][Full Text] [Related]
31. Incidence, clearance, persistence and factors related with high-risk anal HPV persistence in South-East Asian MSM and transgender women.
Yunihastuti E; Teeratakulpisarn N; Jeo WS; Nilasari H; Rachmadi L; Somia IKA; Sukmawati MDD; Amijaya KAT; Yee IA; Hairunisa N; Hongchookiat P; Trachunthong D; Pankam T; Nonenoy S; Ramautarsing R; Azwa I; Merati TP; Phanuphak P; Phanuphak N; Palefsky JM
AIDS; 2020 Nov; 34(13):1933-1941. PubMed ID: 32773478
[TBL] [Abstract][Full Text] [Related]
32. Neovaginal Human Papillomavirus Prevalence in Transfeminine Individuals: A Systematic Review.
Nandwana D; Hawes K; Zuend CF; Pope R
Obstet Gynecol; 2023 Aug; 142(2):296-306. PubMed ID: 37411025
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of high-risk human papillomavirus genotypes in two regions of Peru.
Jelinek K; Harding L; Briceno R; Li Z; Niezgoda A; Sergent S; Etchebarne B
Int J Gynaecol Obstet; 2021 Sep; 154(3):544-549. PubMed ID: 33507540
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of higher-grade dysplasia in persistently high-risk human papillomavirus positive, cytology negative women after introduction of the new cervical cancer screening in Germany.
Berger L; Wolf-Breitinger M; Weiß C; Tuschy B; Berlit S; Sütterlin M; Spaich S
Cancer Causes Control; 2023 May; 34(5):469-477. PubMed ID: 36854989
[TBL] [Abstract][Full Text] [Related]
35. Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark - the SHADE.
Thorsteinsson K; Ladelund S; Storgaard M; Katzenstein TL; Johansen IS; Pedersen G; Rönsholt FF; Nielsen LN; Nilas L; Franzmann M; Obel N; Lebech AM; Bonde J
BMC Infect Dis; 2019 Aug; 19(1):740. PubMed ID: 31438877
[TBL] [Abstract][Full Text] [Related]
36. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
37. The effect of HIV infection on anal and penile human papillomavirus incidence and clearance: a cohort study among MSM.
Mooij SH; van Santen DK; Geskus RB; van der Sande MA; Coutinho RA; Stolte IG; Snijders PJ; Meijer CJ; Speksnijder AG; de Vries HJ; King AJ; van Eeden A; van der Loeff MF
AIDS; 2016 Jan; 30(1):121-32. PubMed ID: 26474302
[TBL] [Abstract][Full Text] [Related]
38. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening.
Volesky KD; Magnan S; Mayrand MH; Isidean SD; El-Zein M; Comète E; Franco EL; Coutlée F
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):851-857. PubMed ID: 35131879
[TBL] [Abstract][Full Text] [Related]
39. HPV Screening Test for the Detection of Precancerous Cervical Lesions and Cervical Cancer in Israeli Women.
Feinberg T; Yehuda-Shnaidman E; Wolf T; Sandbank J; Segal J; Vaknin Z; Schejter E
Acta Cytol; 2021; 65(6):494-500. PubMed ID: 34515031
[TBL] [Abstract][Full Text] [Related]
40. Sexual behaviours associated with incident high-risk anal human papillomavirus among gay and bisexual men.
Wong IKJ; Poynten IM; Cornall A; Templeton DJ; Molano M; Garland SM; Fairley CK; Law C; Hillman RJ; Polizzotto MN; Grulich AE; Jin F;
Sex Transm Infect; 2022 Mar; 98(2):101-107. PubMed ID: 33727339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
